Veradermics (MANE) Consolidated Net Income (2025 - 2026)
Veradermics (MANE) posted Consolidated Net Income of -$27.2 million for Q1 2026, down 119.61% on a QoQ basis from -$12.4 million in Q1 2025, and down 119.61% year-over-year from $138.8 million in Q1 2025.
Veradermics (MANE) Consolidated Net Income (2025 - 2026) Analysis & Trends
Veradermics' Consolidated Net Income history runs 2 years deep, the most recent figure standing at -$27.2 million for Q1 2026.
- Quarterly Consolidated Net Income fell 119.61% year-over-year to -$27.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$39.6 million (changed N/A YoY) and the FY2025 annual result came in at -$70.0 million, down 164.25% from the prior year.
- Consolidated Net Income was -$27.2 million for Q1 2026 at Veradermics, down from -$12.4 million in the prior quarter.
- Across five years, Consolidated Net Income topped out at -$12.4 million in Q1 2025 and bottomed at -$27.2 million in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Consol Net Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Veradermics | 2.63 Bn | 2.63 Bn | - | -27.23 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -27.23 Mn |
| Mar 31, 2025 | -12.40 Mn |